JP2020510085A5 - - Google Patents

Download PDF

Info

Publication number
JP2020510085A5
JP2020510085A5 JP2019570355A JP2019570355A JP2020510085A5 JP 2020510085 A5 JP2020510085 A5 JP 2020510085A5 JP 2019570355 A JP2019570355 A JP 2019570355A JP 2019570355 A JP2019570355 A JP 2019570355A JP 2020510085 A5 JP2020510085 A5 JP 2020510085A5
Authority
JP
Japan
Prior art keywords
salt
pharmaceutically acceptable
pharmaceutical composition
composition according
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019570355A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510085A (ja
JP6917078B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/022068 external-priority patent/WO2018165673A1/en
Publication of JP2020510085A publication Critical patent/JP2020510085A/ja
Publication of JP2020510085A5 publication Critical patent/JP2020510085A5/ja
Priority to JP2021115155A priority Critical patent/JP7315248B2/ja
Application granted granted Critical
Publication of JP6917078B2 publication Critical patent/JP6917078B2/ja
Priority to JP2023111463A priority patent/JP2023126939A/ja
Priority to JP2025167137A priority patent/JP2026009978A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019570355A 2017-03-10 2018-03-12 抗菌化合物、組成物、及びそれらの使用 Active JP6917078B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021115155A JP7315248B2 (ja) 2017-03-10 2021-07-12 抗菌化合物、組成物、及びそれらの使用
JP2023111463A JP2023126939A (ja) 2017-03-10 2023-07-06 抗菌化合物、組成物、及びそれらの使用
JP2025167137A JP2026009978A (ja) 2017-03-10 2025-10-03 抗菌化合物、組成物、及びそれらの使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762470039P 2017-03-10 2017-03-10
US201762470025P 2017-03-10 2017-03-10
US62/470,025 2017-03-10
US62/470,039 2017-03-10
PCT/US2018/022068 WO2018165673A1 (en) 2017-03-10 2018-03-12 Antimicrobial compounds, compositions, and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021115155A Division JP7315248B2 (ja) 2017-03-10 2021-07-12 抗菌化合物、組成物、及びそれらの使用

Publications (3)

Publication Number Publication Date
JP2020510085A JP2020510085A (ja) 2020-04-02
JP2020510085A5 true JP2020510085A5 (enExample) 2021-04-08
JP6917078B2 JP6917078B2 (ja) 2021-08-11

Family

ID=63446316

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019570355A Active JP6917078B2 (ja) 2017-03-10 2018-03-12 抗菌化合物、組成物、及びそれらの使用
JP2021115155A Active JP7315248B2 (ja) 2017-03-10 2021-07-12 抗菌化合物、組成物、及びそれらの使用
JP2023111463A Pending JP2023126939A (ja) 2017-03-10 2023-07-06 抗菌化合物、組成物、及びそれらの使用
JP2025167137A Pending JP2026009978A (ja) 2017-03-10 2025-10-03 抗菌化合物、組成物、及びそれらの使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021115155A Active JP7315248B2 (ja) 2017-03-10 2021-07-12 抗菌化合物、組成物、及びそれらの使用
JP2023111463A Pending JP2023126939A (ja) 2017-03-10 2023-07-06 抗菌化合物、組成物、及びそれらの使用
JP2025167137A Pending JP2026009978A (ja) 2017-03-10 2025-10-03 抗菌化合物、組成物、及びそれらの使用

Country Status (14)

Country Link
US (5) US20210139522A1 (enExample)
EP (2) EP3592430B1 (enExample)
JP (4) JP6917078B2 (enExample)
KR (5) KR102684529B1 (enExample)
CN (2) CN113476469B (enExample)
AU (5) AU2018230805B2 (enExample)
BR (2) BR112019018615B1 (enExample)
CA (1) CA3055932A1 (enExample)
DK (1) DK3592430T3 (enExample)
ES (1) ES2987873T3 (enExample)
FI (1) FI3592430T3 (enExample)
MX (1) MX391911B (enExample)
PT (1) PT3592430T (enExample)
WO (2) WO2018165673A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11795192B2 (en) 2017-03-10 2023-10-24 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
US12030908B2 (en) 2017-03-10 2024-07-09 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
CN112839662A (zh) * 2018-10-17 2021-05-25 莱克伍德阿美达克斯股份有限公司 用于治疗口腔粘膜炎的方法和组合物
US11464783B2 (en) 2019-06-06 2022-10-11 Aligos Therapeutics, Inc. Heterocyclic compounds
CN111534458B (zh) * 2020-04-13 2022-01-14 浙江工业大学 无色杆菌tbc-1及其在降解1,3,6,8-四溴咔唑中的应用
MX2023008829A (es) * 2021-07-22 2023-08-10 Lakewood Amedex Inc Metodos para preparar bisfosfocinas.
US20240245717A1 (en) * 2022-12-14 2024-07-25 Lakewood Amedex, Inc. Antiviral compounds, compositions, and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4421769A (en) 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
US5153230A (en) 1989-10-06 1992-10-06 Perfective Cosmetics, Inc. Topical skin cream composition
US7868162B2 (en) * 1998-12-30 2011-01-11 Lakewood-Amedex, Inc. Antimicrobial and antiviral compounds and methods for their use
US20020032164A1 (en) * 1998-12-30 2002-03-14 Dale Roderic M. K. Antimicrobial compounds and methods for their use
US6211349B1 (en) * 1998-12-30 2001-04-03 Oligos Etc., Inc. Protonated/acidified nucleic acids and methods of use
US6211162B1 (en) 1998-12-30 2001-04-03 Oligos Etc. Inc. Pulmonary delivery of protonated/acidified nucleic acids
BRPI0008131B8 (pt) * 1999-02-12 2021-05-25 Daiichi Sankyo Co Ltd composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno
US6825348B2 (en) * 2002-06-25 2004-11-30 Academia Sinica Antiviral compounds
US8227431B2 (en) 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
WO2010036945A2 (en) * 2008-09-26 2010-04-01 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
CN101724001A (zh) * 2008-10-24 2010-06-09 汪明 一类药用嘧啶衍生物的合成方法
US8551963B2 (en) * 2008-11-06 2013-10-08 Ambit Biosciences Corporation Imidazolothiazole compounds and methods of use thereof
US8884000B2 (en) * 2010-02-17 2014-11-11 Albert Einstein College Of Medicine Of Yeshiva University Saporin-L1 inhibitors and uses thereof
EP2601205A2 (en) * 2010-08-03 2013-06-12 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Guanine nucleotide derivatives for treating bacterial infections
US9062088B2 (en) * 2010-11-02 2015-06-23 Snu R&Db Foundation CDK-inhibiting pyrrolopyrimidine carboxamide derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing the same as active ingredient for preventing or treating hepatocellular carcinoma
US9809616B2 (en) * 2012-10-29 2017-11-07 Emory University Pyrimidine nucleosides and their monophosphate prodrugs for the treatment of viral infections and cancer
WO2014124430A1 (en) * 2013-02-11 2014-08-14 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
US20150037282A1 (en) * 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
US8889701B1 (en) * 2013-10-11 2014-11-18 Alla Chem, Llc Substituted (S)-(2R,3R,5R)-3-hydroxy-(5-pyrimidin-1-yl)tetrahydrofuran-2-ylmethyl aryl phosphoramidate
KR20260035292A (ko) * 2017-06-12 2026-03-12 레이크우드 아메덱스, 인크. 비스포스포신 겔 제제 및 이의 용도

Similar Documents

Publication Publication Date Title
JP2021001196A5 (enExample)
JP2020189864A5 (enExample)
JP2021191784A5 (enExample)
JP2021063088A5 (enExample)
JP2024516371A5 (enExample)
JP2020097577A5 (enExample)
JP2024071370A5 (enExample)
JPWO2023027198A5 (enExample)
JP2019525899A5 (enExample)
JP2020505423A5 (enExample)
JP2020512337A5 (enExample)
JP2010077141A5 (enExample)
JP2003509349A5 (enExample)
RU2010118022A (ru) Фармацевтическая композиция валсартана
JP2016512517A (ja) ロイコトリエンa4加水分解酵素を阻害する方法
FI3592430T3 (fi) Antimikrobisia yhdisteitä, koostumuksia ja niiden käyttöjä
JP2024544538A5 (enExample)
JP2000159790A5 (enExample)
JP2019151627A5 (enExample)
TW469132B (en) Antiviral combinations
JP2022503733A5 (enExample)
JP2021091670A5 (enExample)
JP2022529814A5 (enExample)
JP2020504165A5 (enExample)
CA2679915A1 (en) Novel sulfonated sugar compound and use thereof as medicine